Roshni Dasgupta

A San Diego medtech company quietly crossed $1B in annual revenue. Not valuation. Revenue. Decades of R&D, regulatory grind, and product iteration turned into real scale of helping those with diabetes. Hard tech wins rarely go viral - they endure. Listen in with Fred Grier: https://lnkd.in/gthnjZYn

37

2 Comments

Every operator, consultant, and banker with a network is realizing the same thing. Why advise on deals when you can lead them? Smart professionals are launching funds at record pace. The pattern is obvious. Healthcare executives launching biotech funds. Former operators starting B2B software funds. Industry veterans are tired of watching generalist VCs fumble deals in their space. Specialization beats generalization. Experience beats connections. Your track record speaks louder than your pedigree. Your network matters more than your alma mater. The old barriers to fund formation are dissolving. Technology platforms handle back office operations. Limited partners are diversifying beyond traditional institutional investors. The smart money is following the smart people. The result: A new generation of fund managers who actually understand the businesses they invest in. The question is not whether this trend continues. The question is whether you join it or watch from the sidelines.

24

7 Comments

The “Last Year’s Budget” Trap 🪤 If you frozen your budget today and started from zero, would you still make the same bets? Most CEOs say no. Yet, most companies’ capital allocation looks 90% like the year before. Most companies do not have a capital allocation problem. They have a reallocation inertia problem. It is the silent killer: last year’s plan becomes the default, so capital stays trapped in yesterday’s bets even as CAC, margins, and product velocity shift beneath your feet. A real pattern I see a lot: CAC up 30 to 50%, payback stretches from ~8 months to ~14 months, and the budget still says “last year + 8%. That’s not a plan. That’s annual planning on autopilot. In Part 2 of my Capital Allocation series, we’re breaking down the metrics and considerations that actually matter when deciding where to double down. What’s inside: 1️⃣ The 5 destinations: every dollar of free cash flow has only five places to go, and each needs a different lens 2️⃣ Gross profit is the fuel: allocating by revenue can quietly underfund your best products 3️⃣ Maintenance vs growth: why moonshots belong in the CEO’s cost center, not buried in business units 4️⃣ The AI cash trap: how top-line wins can still crush optionality if inference and delivery costs are not gated 5️⃣ Decompose LTV/CAC: compound metrics are fine for monitoring, but they hide the levers you actually need to pull True zero-based budgeting is frankly too time consuming to run every year. But you can steal the spirit: do not inherit last year’s assumptions. Re-justify the rationale with what you know today. ✅ Budgets don’t create value. Reallocation does. ❇️ Your best advantage isn’t planning harder. It’s reallocating faster. Read Part 2 here:

6

1 Comment

The Compliance Wall: Why #D2Cfounders stop halfway. Most D2C health founders never attempt to get a pharmaceutical license. Not because they don't see the value but because the sheer weight of compliance and complexity is paralyzing. They stick to simple OTC products because the alternative involves drug inspectors, hiring pharmacists, rigorous audits, and endless regulatory maintenance. It is a full time battle that distracts from building a brand. But avoiding this complexity is the single biggest cap on your revenue. Here is the symmetry between the Compliance Barrier you avoid and the Growth Engine you are missing: 1. The Acquisition Link • The Complexity: Gaining LegitScript certification requires a flawlessly documented supply chain. It feels impossible to start. • The Unlock: A compliant partner clears this hurdle instantly. Suddenly, you aren't fighting the ad platforms (Google/Meta); you are dominating them with lower CAC. 2. The AOV Link • The Complexity: Dispensing prescription (Rx) products requires a Licensed Pharmacist on staff and strict dispensing protocols. • The Unlock: When the supply chain is licensed, you can bundle Rx + OTC. Your ₹600 cart instantly becomes a ₹2500 treatment plan. 3. The Trust Link • The Complexity: Building a medical grade verification system from scratch is resource heavy and full of compliance issues. • The Unlock: Borrowed Authority. Displaying valid pharmacy credentials on your online store increases conversion rates by 30%. This is why DocPharma exists. We didn't just build a supply chain; we built a Regulatory Shield. As India’s first Compliant #B2B2CQuickCommerce Supply Chain, we have already fought the battles you are avoiding. We hold the licenses (Wholesale, Retail,FSSAI), manage the pharmacists, prescriptions, doctors, diagnostics and handle the compliances. You scale the #Brand. We absorb the #Complexity. Silence becomes power when your infrastructure has already fought the battles. #D2CIndia #HealthTech #RegulatoryStrategy #Growth #SupplyChain

24

1 Comment